Hong Kong-listed innovative pharmaceutical concept stocks have been fluctuating and rising, with Novartis Health Huaxia surging by over 10%.

Hong Kong concept stocks of innovative drugs fluctuated and rose, with Novartis Health increasing by over 10%, GAL Pharmaceutical-B rising by over 8%, and Shandong Xinhua Pharmaceutical, Zhaoyan new drugs, and Xinda Biological following the trend.